文献速递艾滋病与性传播感染医院感染防控

当前抗逆转录病毒治疗时代下HIV感染者基于CD4计数和年龄的社区获得性肺炎与带状疱疹发病率:纵向队列研究

Incidence of Community-acquired Pneumonia and Herpes Zoster in People With HIV Based on CD4 Count and Age in the Current Antiretroviral Therapy Era: A Longitudinal Cohort Study.
PubMed 文献 · Clin Infect Dis · 2026-01-01

该全国性队列研究纳入2010至2023年所有≥18岁接受治疗的HIV感染者,按年龄、CD4计数和抗逆转录病毒治疗(ART)时长分层计算社区获得性肺炎(CAP)和带状疱疹(HZ)的发病率。结果显示CD4≤200 cells/µL者发病率最高,而CD4≥500 cells/µL且ART≥1年者的风险与一般人群相当。

要点

  • CD4≤200 cells/µL的HIV感染者CAP和HZ发病率最高。
  • CD4≥500 cells/µL且ART≥1年者风险与一般人群相当。
  • 疫苗推荐可考虑对免疫重建良好者与一般人群一致。

核心结论

  • CD4≤200 cells/µL和/或未接受ART的HIV感染者CAP和HZ发病率最高,而CD4≥500 cells/µL且ART≥1年者风险与一般人群相当。

研究设计与样本

  • 全国性纵向队列研究,纳入2010至2023年间所有≥18岁接受治疗的HIV感染者,计算CAP和HZ发病率每1000人年随访(PYFU),按年龄、CD4计数和ART时长分层。

主要发现

  • CD4≤200 cells/µL者CAP发病率为34至107/1000 PYFU,HZ为9至63/1000 PYFU,取决于年龄。
  • CD4≥500 cells/µL且ART≥1年者CAP发病率为5至20/1000 PYFU,HZ为4至5/1000 PYFU,取决于年龄。

临床怎么用

  • 对于长期抑制性ART且免疫重建良好的HIV感染者,疫苗推荐可与一般人群一致;HIV特异性疫苗策略可能仍适用于病毒学失败和/或免疫重建不良者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: People with HIV (PWH) using antiretroviral therapy (ART) remain at increased risk for infections such as community-acquired pneumonia (CAP) and herpes zoster (HZ), for which vaccinations are recommended. However, these recommendations do not consider the combined effects of age, CD4 count, and duration of ART on infection risk. We assessed how these factors influence CAP and HZ incidence to better tailor vaccination strategies. METHODS: We used data from a nationwide cohort study including all PWH aged ≥18 years in care between 2010 and 2023. All documented CAP and HZ episodes were included, and incidence rates were calculated per 1000 person-years of follow-up (PYFU), stratified by age, CD4 count, and ART duration. RESULTS: Community-acquired pneumonia and herpes zoster incidence rates were highest in PWH with CD4 ≤ 200 cells/µL, ranging from 34 to 107/1000 PYFU for CAP and 9 to 63/1000 PYFU for HZ, depending on age. In those with CD4 ≥ 500 cells/µL and ≥1 year on ART, incidence rates ranged from 5 to 20/1000 PYFU for CAP and 4 to 5/1000 PYFU for HZ, depending on age. CONCLUSIONS: Incidence rates are the highest in PWH with CD4 counts ≤200 cells/µL and/or not on ART, whereas PWH with CD4 counts ≥500 and ≥1 year on ART have a risk of CAP and HZ comparable to that of the general population. These findings support aligning vaccine recommendations for PWH on long-term suppressive ART with immune reconstitution with those for the general population, while HIV-specific vaccination strategies may remain most relevant for individuals with virological failure and/or poor immune reconstitution.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Te Linde E, Wit FWNM, van Welzen BJ, et al. Incidence of Community-acquired Pneumonia and Herpes Zoster in People With HIV Based on CD4 Count and Age in the Current Antiretroviral Therapy Era: A Longitudinal Cohort Study. Clin Infect Dis. 2026. PMID: 41406983. doi:10.1093/cid/ciaf686

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。